Wednesday, June 10, 2026

Patent intelligence Β· US

US 2023130736

METHODS OF TREATING MIGRAINE

granted A61K 31/ 496 A IA61K 31/ 4375 A IA61K 45/ 06 A IA61K/31404
Status granted
Pipeline programs 6
Years to expiry 17
Applicant portfolio 25
Patent details β€” US 2023130736
Jurisdiction
US
Status
granted
Grant date
Apr 27, 2023
Expiration
Apr 22, 2043
CPC classes
A61K 31/ 496 A I, A61K 31/ 4375 A I, A61K 45/ 06 A I, A61K/31404
View on Google Patents β†—

Quick answer

US 2023130736 (METHODS OF TREATING MIGRAINE) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Apr 27, 2023. Expires Apr 22, 2043 (17 years remaining) β€” relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
β€”
CPC classes
A61K 31/ 496 A I, A61K 31/ 4375 A I, A61K 45/ 06 A I, A61K/31404, A61K/314164, A61K/314196

More from ALLERGAN PHARMACEUTICALS INT LTD [IE]

Related pharmaceutical patents in our USPTO index.

  1. US 12383545

    TREATMENT OF MIGRAINE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] Β· Expires Aug 7, 2045

    granted
  2. US 2025064788

    TREATMENT OF MIGRAINE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] Β· Expires Feb 22, 2045

    granted
  3. US 2024180883

    TREATMENT OF MIGRAINE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] Β· Expires Jun 1, 2044

    granted
  4. WO 2024081718

    ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] Β· Expires Apr 13, 2044

    granted
  5. CA 3244873

    TRAITEMENT PRÉVENTIF DE LA MIGRAINE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] Β· Expires Sep 9, 2043

    granted
  6. WO 2023077094

    TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR

    ABBVIE INC [US] Β· Expires Apr 29, 2043

    granted
  7. US 2022380379

    PHARMACEUTICAL COMPOUNDS

    HEPTARES THERAPEUTICS LTD [GB] Β· Expires Nov 26, 2042

    granted

Frequently asked questions

What is US patent 2023130736?

US 2023130736 (METHODS OF TREATING MIGRAINE) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Apr 27, 2023. Expires Apr 22, 2043 (17 years remaining) β€” relevant for patent-cliff and LOE planning.

Who owns US 2023130736?

ALLERGAN PHARMACEUTICALS INT LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does US 2023130736 expire?

Our index shows an expiration date of Apr 22, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.